About Dianomi Therapeutics
Dianomi Therapeutics is a company based in Madison (United States) founded in 2017. Dianomi Therapeutics has raised $3 million across 3 funding rounds from investors including HHS and Ligand Pharmaceuticals. Dianomi Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Madison, United States
-
Sectors
HealthcareChemicals & Materials
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3 M (USD)
in 3 rounds
-
Latest Funding Round
$251.88 K (USD), Grant
Sep 01, 2020
-
Investors
HHS
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Dianomi Therapeutics
Dianomi Therapeutics has successfully raised a total of $3M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $251.88 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dianomi Therapeutics
Dianomi Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Dianomi Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dianomi Therapeutics
Investment portfolio details for Dianomi Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dianomi Therapeutics
Detailed financials for Dianomi Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dianomi Therapeutics Comparisons
Peer comparison for Dianomi Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dianomi Therapeutics
Dianomi Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Dianomi Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dianomi Therapeutics
Complete news archive for Dianomi Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dianomi Therapeutics
Dianomi Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Dianomi Therapeutics is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Barry Kurokawa is the current CEO of Dianomi Therapeutics.
Dianomi Therapeutics is a funded company, having raised a total of $3M across 3 funding rounds to date.
Dianomi Therapeutics was founded in 2017 in Madison, United States, focusing on the biotechnology sector. Therapies targeting inflammatory conditions, such as osteoarthritis and pain, are developed using a proprietary Mineral Coated Microparticle (MCM) platform. This technology enables sustained drug release and enhances efficacy and safety by mimicking mineralized tissues like bones and teeth. Applications extend to protein biologics and small molecules across various treatments.
Dianomi Therapeutics's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Dianomi Therapeutics has 2 investors. Key investors include HHS, and Ligand Pharmaceuticals.